Welcome to our dedicated page for Matinas BioPharma Holdings news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas BioPharma Holdings stock.
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) is a clinical-stage biopharmaceutical company dedicated to advancing innovative anti-infective therapies for orphan indications. Utilizing proprietary lipid-crystal nano-particle cochleate technology, Matinas BioPharma aims to enhance the safety, tolerability, and oral bioavailability of existing drugs, thereby reducing their toxicity and improving patient outcomes.
The company's leading drug candidate, MAT2203, is an orally-administered, encochleated formulation of amphotericin B, a broad-spectrum fungicidal agent. Currently in Phase 2 clinical trials, MAT2203 seeks to offer a less toxic and more effective oral treatment for severe fungal infections.
Another promising candidate is MAT2501, an orally-administered, encochleated formulation of amikacin. Amikacin is a broad-spectrum aminoglycoside antibiotic agent effective against acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram-negative bacterial infections. MAT2501 is currently in Phase 1 clinical trials, following an open Investigational New Drug (IND) application.
Matinas BioPharma's innovative approach positions the company at the forefront of developing next-generation anti-infective therapies. The firm's pipeline also includes other drug candidates that aim to address unmet medical needs in infectious disease treatment. By leveraging its nano-encapsulation technology, Matinas BioPharma is committed to creating safer and more effective treatments for patients.
Latest News:
- A photo accompanying this announcement is available
- Studies in neutropenic mouse model demonstrate prolonged and enhanced survival, reduced fungal burden, and improvement in lung infection.
- Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100
Matinas BioPharma Holdings (MTNB) reported significant progress with MAT2203, its lead candidate for cryptococcal meningitis, enrolling 75% of patients in Cohort 4 of the EnACT study. Topline data is expected by early Q4 2022. The FDA has clarified a streamlined Phase 3 trial design, with an anticipated start in Q1 2023. The company has $38.5 million in cash, adequate to support operations through 2023. Management expects ongoing collaboration with BioNTech on mRNA applications. However, a potential partnership for LYPDISO is halted. The net loss for Q2 2022 was $5.9 million.
Matinas BioPharma (NYSE: MTNB) announced that CEO Jerome D. Jabbour will participate in a fireside chat at the BTIG Biotechnology Conference on August 8, 2022, at 2:00 p.m. ET, alongside investor meetings. This hybrid conference will take place at The St. Regis New York. The company aims to enhance intracellular delivery through its lipid nanocrystal (LNC) platform, developing drug candidates like MAT2203 for antifungal treatments and MAT2501 for bacterial infections. Collaborative efforts include partnerships with BioNTech and Gilead Sciences.
Matinas BioPharma (NYSE: MTNB) announced a conference call on August 11, 2022, at 8:30 a.m. ET to discuss their second-quarter operational and financial results. Interested participants can join by calling (877) 407-5976 or (412) 902-0031 and use conference ID 13730276. The live webcast will be available on the company's website, where it will also be archived for 90 days. Matinas focuses on enhancing the intracellular delivery of nucleic acids and small molecules using its lipid nanocrystal (LNC) platform.
Matinas BioPharma (MTNB) announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has recommended MAT2203 for orphan medicinal product designation for treating cryptococcosis. Previously, the FDA granted MAT2203 Orphan Drug, QIDP, and Fast Track designations. This designation provides potential market exclusivity and reduction in application fees. MAT2203 is an oral formulation of amphotericin B, currently completing Phase 2 trials, targeting invasive fungal infections like cryptococcal meningitis.
Matinas BioPharma (NYSE AMER: MTNB) will be represented by CEO Jerry Jabbour at the LD Micro Invitational XII Conference on June 7, 2022, at 3:30 p.m. ET in Westlake Village, California. Investors interested in meeting management can coordinate through the conference. A live webcast of the presentation will be accessible via the Company’s website, with a replay available for 90 days post-event. Matinas focuses on advancing its lipid nanocrystal (LNC) technology for drug delivery, currently developing two clinical assets: MAT2203 and MAT2501.
Matinas BioPharma announced a collaboration with BioNTech to combine mRNA with its lipid nanocrystal (LNC) technology. Enrollment for Cohort 4 of the EnACT study for MAT2203 is ongoing, with topline data expected in Q3 2022. Feedback from a recent FDA meeting suggests a streamlined pathway for a New Drug Application with just one confirmatory trial for MAT2203. The company reported $43.9 million in cash, sufficient to fund operations through 2023, despite a net loss of $6.0 million in Q1 2022.
Matinas BioPharma Holdings (MTNB) announced a conference call on May 12, 2022, at 8:30 AM ET to discuss Q1 2022 operational and financial results. The company focuses on innovative intracellular delivery technologies using its lipid nanocrystal platform. Key assets include MAT2203, an oral antifungal in Phase 2 trials, and MAT2501, an oral formulation for bacterial infections currently in Phase 1. Collaborations with leading firms like BioNTech and Gilead strengthen its pipeline. The webcast will be available on Matinas' website and archived for 90 days.
Matinas BioPharma (MTNB) announced that CEO Jerry Jabbour is set to present at the 12th Annual BioNJ BioPartnering Conference, occurring virtually from May 9-13, 2022. His presentation is scheduled for May 10, from 11:00 a.m. to 12:30 p.m. ET. The conference aims to foster collaboration in the biopharmaceutical sector, and the company will leverage the BioPartnering 1:1 feature for one-on-one meetings. Matinas BioPharma focuses on innovative intracellular delivery solutions using its lipid nanocrystal platform and is currently advancing several product candidates, including MAT2203 and MAT2501.
BioNTech and Matinas BioPharma have announced an exclusive research collaboration to enhance mRNA vaccine formulations using Matinas' Lipid Nanocrystal (LNC) Delivery Platform Technology. The partnership aims to explore innovative approaches, including potential oral vaccines. Matinas will receive an upfront access fee and further research funding from BioNTech. Discussions for a licensing agreement for the LNC technology have also begun. This collaboration is viewed as a significant validation for Matinas' delivery platform, potentially benefiting millions through improved vaccine delivery methods.
Matinas BioPharma (MTNB) announced that CEO Jerry Jabbour will present at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 3:00 p.m. ET. Investors can arrange virtual meetings through the conference coordinator. The presentation will be available via webcast and archived on the company’s website for 90 days. Matinas focuses on advancing its lipid nanocrystal technology for drug delivery, with ongoing clinical trials for MAT2203 and MAT2501, targeting fungal and bacterial infections, respectively.
FAQ
What is the current stock price of Matinas BioPharma Holdings (MTNB)?
What is the market cap of Matinas BioPharma Holdings (MTNB)?
What is Matinas BioPharma Holdings, Inc.?
What is MAT2203?
What is MAT2501?
What technology does Matinas BioPharma use?
What are the benefits of MAT2203?
What types of infections does MAT2501 target?
What is unique about Matinas BioPharma's approach?
Who can I contact for investor relations inquiries?
What is the status of MAT2203 clinical trials?
What recent achievements has Matinas BioPharma reported?
